Rubicon Research’s IPO, backed by Arihant Capital with a “Subscribe” rating, highlights the company’s strong growth and diversified pharma portfolio. The US-focused generics and specialty drug player has seen revenue jump to Rs 12,962 crore in FY25 and net profit rebound to Rs 1,344 crore. The IPO is fairly valued, aiming to attract both institutional and retail investors.